Neurological disease that impacts the sensory pathway can produce severe chronic pain, also known as neuropathic pain. This usually is unrelated to any peripheral tissue injury. This occurs with disorders of the central nervous system (CNS), such as stroke and multiple sclerosis, or with conditions associated with peripheral nerve damage, such as mechanical injury, diabetic neuropathy or herpes zoster infection.
On form of neuropathic pain that is just now gaining recognistino is complex regional pain syndrome (CRPS), also known as reflex sympathetic dystrophy (RSD). This pain is often burning in nature and is usually caused by an injury involving variable sensory, motor, autonomic and trophic changes. There can be many causes for CRPS. For the most part, it is the result of an accidental trauma. This trauma can be minor, as with a cut, sprain or fracture or more severe, as with a major crush injury or post-surgical procedure.
Because the sympathetic nervous system affects so many different systems of the body, RSD-CRPS is a complex and little understood disorder, and provides a unique and underserved market opportunity for pain management products.
This briefing analyzes the potential world market for treatments for CRPS-RSD. The report generally reviews the nature and direction of research, as well as future markets. This briefing also profiles several companies involved in developing such products in the field, as well as treatments for neuropathic pain that could eventually be applied to treat CRPS. Such companies include AlgoRx Pharmaceuticals, Cell Targeting Technologies and NeurogesX.
Market forecasts, made through 2009 for four major global regions, are based on an examination of current market conditions and on investigations into the development of new products by key companies. This information is also weighted with the projected timing and the potential for receiving regulatory approvals to market products. The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with company executives, clinicians, researchers and public health officials.